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Background & objectives: Survival pattern among children infected with the human immune deficiency 
virus (HIV) follows a bimodel distribution. Some children survive beyond 9 years age and are known as 
long term survivers (LTS) while others had a more rapid course to death during the first few years of life. 
In the LTS group of children, two sub-populations have emerged, the long term non-progressors (LTNP) 
who have remained asymptomatic over a period of years and those who have survived despite clinical 
and laboratory evidence of disease progression, the long term progressors (LTP). The aim of the present 
study was to determine the factors influencing the conversion of LTNPs to LTPs in a group of perinatally 
HIV infected children who were followed up for five years.
Methods: A total of 26 HIV seropositive paediatric patients were monitored from 2006 to 2011 with CD4 
cell counts, onset of clinical manifestations, body weight, biochemical, haematological and immunological 
parameters. Statistical analyses, both qualitative and quantitative, were used to determine the degree of 
conversion of non-progressors to progressors.
Results: All 26 (13 female and 13 male) perinatally HIV infected children, born during1991-1996 were 
healthy until 2006. But by 2011, 18 were placed in progressors group with antiretroviral therapy (ART), 
while six remained in non progressors group and two died. As per the Kaplan-Meier survival analysis, 
AIDS free median survival period (years) in LTP group (CD4 count) of the cohort was 10±0.66 (<200; 
P=<0.05); 11±0.61 (200-350, P=<0.05), 12±0.18 (>350, P=<0.05). Intercurrent and opportunistic infections 
(OIs) were observed in LTPs only. The incidence of OI in LTPs was higher when compared to general 
paediatric population.
Interpretation & conclusions: Our findings show that CD4 counts and OIs play an important role in 
influencing the survival chances of perinatally HIV infected children.
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 The total number of people living with human 
immunodeficiency virus (HIV) infection in India 
is very high (as much as 2.5 millions), including an 
estimated 0.09 million paediatric HIV patients1. Mean 
duration of survival after diagnosis of HIV infection 
in India is 92 months1. Perinatal transmission is the 
most common mode of acquiring HIV in the paediatric 
age group and is responsible for about 67 to 87 per 
cent of paediatric HIV infection2. The clinical features 
of HIV infection in children are different from those 
in adults3. One of the most striking characteristics of 
HIV-1 infection is its individual variability in terms of 
the time required to progress towards AIDS. A small 
percentage (5%) of HIV-1 infected children remain 
free from AIDS-defining illnesses for longer than 9-10 
yr in the absence of therapy and are termed as long 
term survivors (LTS). The LTS group of children is 
differentiated into two subgroups, the long term non 
progressors (LTNPs) and long term progressors (LTP).
 LTNPs are HIV-infected individuals who have 
remained asymptomatic over a period of years and 
have maintained CD4-positive lymphocyte counts 
greater than 500 cells/µl (in Indian populations normal 
range 304-1864 cells/µl)4 without receiving therapy. 
LTPs represent the individuals who have survived 
despite clinical and laboratory evidence of diseases 
progression. LTNPs represent an important group of 
HIV infected individuals to study because of their 
potentially unique resistance to virus infection due 
to innate immune responses. An understanding of the 
clinical profile of LTNPs would provide an insight 
into the parameters that may influence the survival 
probability and the extent of LTNP conversion to LTPs, 
requiring antiretroviral treatment (ART). The present 
study was undertaken on a group of 26 perinatally HIV 
infected children who were followed up for five years 
to determine the factors influencing the conversion of 
LTNPs to LTPs.
Material & Methods
 This is a descriptive study based on the data 
collected from a group of children infected with 
HIV from perinatal transmission being followed up 
prospectively from birth.
Study subjects:  This study initiated in August 2006 
was conducted on 26 HIV perinatally infected children 
born between 1991-1996 in the LODI multipurpose 
voluntary organization hospital, Warangal, Andhra 
Pradesh, India. These children were followed up at 
MGM Hospital affiliated to Kakatiya Medical College, 
Warangal. HIV infection was diagnosed by rapid tests 
and was finally confirmed with the Western blot and 
PCR. The study proposal was approved by the following 
two institutes’ ethics committees, Kakatiya Medical 
College, Warangal and University of Hyderabad, 
Hyderabad.
Inclusion criteria: Perinatally HIV infected children, 
who were >9 yr age (as on August 2006), had >300 
CD4 cells/µl, no opportunistic infections, WHO-Stage 
1 (Normal and asymptomatic) and were not receiving 
ART5,6.
Exclusion criteria: Children who were not perinatally 
infected and were <9 yr of age (as on August 2006), 
had <300 CD4 cells/µl, HIV-opportunistic infections, 
WHO-Stages II, III, IV and under ART.
Case definitions: In this study group of 26 children, 
baseline CD4 counts, BMI, onset of opportunistic 
infections, biochemical parameters [bilirubin, serum 
albumin, serum glutamic oxaloacetic transaminase 
(SGOT), serum glutamic-pyruvic transaminase (SGPT), 
alkaline phosphatase, gamma-glutamyl transferase 
(GGT), serum amylase, blood urea nitrogen, serum 
creatinine and haematology parameters complete blood 
picture (CBP), total lymphocyte count (TLC), Hb, 
erythrocyte sedimentation rate (ESR)] were monitored 
from 2006 to 2011. No disease progression to AIDS 
was monitored with the above parameters at every six 
month intervals over a period of five years.
 CD4 absolute counts and percentage were estimated 
at two places by flow cytometry (FACSCalibur, 
MultiSETV2.2, USA) at the Kakatiya Medical College, 
Warangal as well as at the University of Hyderabad, for 
the purpose of validation and to minimize bias.
Clinical evaluation: The baseline health status of the 
patients was reviewed every six months. Relevant 
investigations like chest X-ray, Mantoux test, 
aspiration cytology, ultrasonography, neuroimaging, 
were conducted and other clinical and laboratory 
parameters (anaemia, complete blood picture, 
cervical lymphadenopathy, bronchitis, otitis media, 
cardiomegaly, dermatitis, hepatomegaly, pneumonitis, 
granulomatous disease of brain, scabies, oral candidiasis, 
meningitis, glaucoma, non-Hodgkin’s lymphoma of 
Burkitt type, toxoplasmosis of brain) were recorded. 
Patients were treated symptomatically based on their 
clinical presentation. Opportunistic infections were 
treated with a course of antibiotics.
Statistical analysis: Statistical analysis was performed 
using the statistical software package SPSS Inc., 
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Chicago, USA (Windows, version 17.0). Kaplan-
Meier survival analysis was used to estimate median 
probabilities and cumulative probabilities with 95% 
confidence intervals. The non parametric Chi-square 
test and t-test were also applied in comparative analysis 
results between different groups. 
Results
 A total of 26 HIV perinatally infected paediatric 
patients fulfilling all relevant criteria were enrolled as 
long term non progressors in August 2006. Subsequently, 
at the end of the study, (by August 2011), 20 (76%) of 
26 patients converted to LTPs and six (24%) remained 
LTNPs (Table I). All six LTNPs were above nine years of 
age and showed absolute CD4 counts >300 cells/µl. As 
per the WHO criteria they were asymptomatic, showed 
normal activity, did not have any WHO defined AIDS 
related illness and were not on ART. When classified 
according to WHO staging system, five children were in 
stage I and one in stage II. In contrast, the 20 patients in 
the LTP group, exhibited AIDS associated opportunistic 
infections and were on antiretroviral treatment. When 
classified according to WHO staging system, 12 (60%) 
were stage I, three (10%) II, one (5%) stage III, four 
(20%) stage IV.
 The CD4 count of the study group ranged from 17 to 
2214/ µl with CD4 mean count of 586±162 cells/ µl for 
LTNPs and at 661±276 cells/ µl for LTPs (Table I). There 
was no significant difference in any parameter between 
the two groups except for serum albumin (P<0.05). 
Haematological abnormalities like anisocytosis, 
macro-ovalocytes, poikilocytosis, microcytosis, 
elliptocytosis, rouleaux formation, tear drop cells, 
transformed lymphocytes and hypersegmented WBC 
were seen both in LTNPs and LTPs. 
 Children in LTP group experienced several OIs 
including cervical lymphaednopathy, bronchitis, 
otitis media, dermatitis, pneumonitis, granulomatous 
disease of brain, scabies, oral candidiasis, meningitis, 
toxoplasmosis of brain and HIV associated malignancy 
like non-Hodgkin’s lymphoma of Burkitt type. No 
opportunistic infections were observed in six children 
in LTNP group.
 No mortality was noticed in the LTNP group but 
in the LTP group two patients died (one with non-
Hodgkin’s Lymphoma of Burkitt type and another with 
toxoplasmosis of brain) (Table II).
 During the study period (2006-2011), the 
progression of LTNP to LTP occurred due to intercurrent 
and opportunistic infections and warranted ART. Table 
III shows a comparison of occurrence of OIs in HIV 
patients and the general paediatric population visiting 
the same hospital during the same period.
Table I. Characteristics of long-term non-progressors (LTNP) and long-term progressors (LTP) groups
Parameter LTNP (n=6) 95% CI LTP (n=20) 95% CI
Age (yr) 15.17±1.94 13.13-17.20 14.65±0.99 14.19-15.11
Height (cm) 133.17±15.04 117.38-148.95 141.40±14.42 134.65-148.15
Weight (kg) 25.67±7.66 17.63-33.71 33.55±9.71 29.00-38.10
BMI (kg/m2) 14.21±1.60 12.54-15.90 16.95±5.80 14.23-19.66
CD4+ T cell (Count/µl) 586.0±162 416.1-755.9 661±276.3 531.3-789.9
CD4+ T cell (%) 25.97±6.30 19.36-32.59 22.38±6.59 19.30-25.47
Bilirubin (mg/dl) 0.875±0.40 0.16-1.70 0.664±0.251 0.01-1.38
Serum albumin (mg/dl) 4.28±0.18 3.30-5.0 3.99±0.39* 0.9-6.50
SGOT (U/l) 58.0±12.1 27.6-100.9 52.9±19.7 19.46-48.4
SGPT (U/l) 39.4±14.8 41.64-45.77 36.3±17.7 3.5-70.2
AP (U/l) 235.8±65.0 100.9-415.5 208.1±66.8 186.57-224.9
GGT(U/l) 16.83±4.36 14.06-23.6 26.9±0.31 21.4-32.4
Serum amylase (U/l)       115.0±41.4 63.56-217.8 133.8±48.8 51.14-198.5
BUN (mg/dl) 15.87±5.40 9.98-22.6 19.02±6.15 8.77-27.2
SC (mg %) 0.908±0.21 0.86-0.99 0.92±0.25 0.29-1.61
AP, alkaline phosphates; SA, serum amylase; BUN, blood urea nitrogen; SC, serum creatinine; SGOT, serum glutamic oxaloacetic 
transaminase; SGPT, serum glutamic-pyruvic transaminase; GGT, gamma-glutamyltransferase; *P<0.05 compared to LTNPs
Survival analysis of LTNPs and LTPs: All non-
progressors were alive until the last data collection 
point. As per the Kaplan-Meier survival analysis the 
incubation period in LTP patients ranged from 9 to 16 
yr. The survival period in LTPs as estimated from the 
analysis and its dependence on CD4 in terms of median 
survival time (MST) in years was 10±0.66 (CI:8.69-
11.30) at CD4 count <200 cells/µl; 11±0.61 yr (CI: 9.8-
12.2) with CD4 count between 200 and 350 cells/µl and 
12±0.18 (CI 11.63-12.37) for CD4 count >350 cells/
µl. The association between CD4 counts and survival 
time was found to be significant (P<0.05). The median 
survival time after ART was 13±0.262 yr (CI: 12.49-
13.51) and the CD4 count was found to >350 cells/µl 
for all the patients in this group.
Discussion
 The progression of the disease and the abnormalities 
associated with HIV/AIDS are influenced by several 
factors such as baseline health and nutritional status, 
environment, endemic diseases and access to therapy. 
The median survival time of perinatally HIV infected 
children is approximately 8 to 9 yr7. Mean survival time 
of Indian patients after diagnosis of HIV is 92 months 
or 8 years7. Median time for progression from HIV 
infection to AIDS was reported to be about 7.9 yr8.
Table II. Profile of antiretroviral therapy (ART) initiation and opportunistic infections (OI)/clinical status in long term progressors
S. No. Sex Year of ART initiation 
(age in yr)
CD4 count/µl at ART initiation 
(95% CI)
OI (age in yr, yr of study)
1 F  2006 (9) 928 (743-2256) Pneumonitis (9, 2006)
Bronchitis (10, 2007)
2 F 2007 (12) 876 (557-1021) None
3 M 2007 (10) 455 (371-1277) Otitis (9, 2006)
Bronchitis (9, 2006)
4 F 2010 (13) 321 (253-590) None
5 F 2008 (11) 297 (255-693) Chronic lymphadenopathy (11, 2008)
6 F 2011 (13) 268 (260-849) Cervical lymphadenopathy (12, 2010) 
Toxoplasmosis of brain (13,2011)
Died (13, 2011)
7 M 2008 (11) 262 (250-849) Bronchitis (10, 2007)
Chronic lymphadenitis (11, 2008)
8 F 2009 (12) 249 (118-1194) None
9 M 2007 (11) 240 (236-1155) None
10 F 2007 (11) 204 (201-516) Granulomatous disease of brain (10, 2006)
Oral candidiasis (11, 2007)
11 M 2006 (11) 199 (185-577) None
12 F 2006 (11) 192 (174-527) Dermatitis (11, 2006)
Pneumonitis (12, 2007)
Bronchitis (13, 2008)
13 F 2007 (12) 174 (160-621) None
14 M 2007 (10) 168 (130-787) None
15 F 2008 (11) 156 (140-1016) None
16 M 2010 (16) 155 (151-549) None
17 M 2006 (9) 129 (125-1183) None
18 F 2009 (12) 115 (105-736) None
19 M 2006 (9) 75 (72-1206) Bronchitis (11, 2008)
Granulomatous disease of brain (11, 2008)
20* M Not given ART* 2027 (922-2081) Burkitt lymphoma (11, 2011)
Died (11, 2011)
*Listed under LTP as disease progressed on the last data collection time
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 The mean age of the LTP children was 13 ± 2.29 yr 
and that of LTNP was 12.83 ± 3.06 yr. Incubation period 
and AIDS free survival period was 9-16 yr in LTPs and 
in LTNPs it ranged from 11 to 19 yr. Median age of 
AIDS progression in perinatally infected HIV children 
in US was reported to be 4.1 yr and that of AIDS free 
children up to 13 yr9. In a European cohort, 36 per cent 
of the perinatally infected children developed AIDS 
by 6 years10. In UK, the reported median age of AIDS 
progression is 5 years and survival time 8 years11. In 
Pediatric Spectrum of Disease project, the estimated 
mean time from birth to progression to AIDS was 4.8 
years and the mean survival time from birth was 9.4 yr12. 
In Rwanda, a 5 year prospective study suggested that 
the mother to child transmission to AIDS progression 
was 2 to 5 years and the estimated median survival 
time was 12.4 months13. According to a study from 
south India1 the mean survival time for adults from 
serodiagnosis was 92 months or 7.6 years1. Studies on 
various perinatally infected paediatric cohorts suggest 
that the onset time of disease progression ranges from 
2 months to 13 years while the incidence time of 
mortality ranges from 3 months to 5 years and by 3 
years as many as 89 per cent of the infected children 
die as reported in an African study14.
 Results from the present study showed that the 
median survival time was about 12 years for the 
LTP group. CD4 counts play a significant role in 
influencing the survival time. An earlier study4 showed 
that persons with a CD4 lymphocyte count <200 cells/
µl were 19 times more likely to have shorter survival 
time than those with CD4 cell count of >350 cells/µl. 
Results from the present study showed that one child 
with high CD4count >700 cells/µl was diagnosed with 
Burkitt’s lymphoma stage IV and died subsequently. 
Kaplan-Meier survival analysis showed that with 
the progression of age the AIDS free survival time 
has decreased thus suggesting a dependence on CD4 
count.
 The nature of OIs associated with perinatally 
HIV infected children differ for cohorts drawn from 
different regions and from different countries. In 
various Indian studies the commonly reported OIs 
are otitis media, oral candidiasis, dermatological 
manifestations, hepatomegaly, and lymphadenopathy15. 
In studies from South Africa, Ethiopia, Rwanda, Italy, 
the OIs reported include otitis media, dermatological 
manifestation, hepatomegaly, lymphadenopathy, with 
deaths occurring at age 5-13 yr12,14,15.
 In our study 11 per cent of LTP group developed 
mild cardiomegaly. In one study cardiac dysfunction 
was reported in 18 to 39 per cent of HIV-infected 
children and this was associated with an increased risk 
Table III. Incidence of opportunistic infections (OIs) in total children compared to paediatric cases referred to the hospital during 
2006-2011
Study children  
n=26*
Children visiting for primary  
care #N=8,500
OI/Intercurrent infection With ART  
(LTP, N=20)




OI (n)  % OI (n)  OI (n)  %
Lymphaednopathy 16 80 Nil 52 0.61
Dermatitis 2 10 Nil  44 0.51
Bronchitis 6 30 Nil  442 5.2
Oral candidiasis 1 5 Nil  2 0.02
Pneumonitis 2 10 Nil  206 2.42
Granulomatous diseases of brain 2 10 Nil  53 0.62
Meningitis 1 5 Nil  20 0.24
Eardischarge (otitis media) 5 25 Nil  25 0.29
Non Hodgkins lymphoma of Burkitt type 1 5 Nil 0 0
Scabies 1 5 Nil 112 1.32
Toxoplasmosis of brain 1 5 Nil 0 0
*Total number of cases in study group -26 (LTNP 6, LTP 20, mortality 2 from LTP group);
#Data archived from medical records of the cases referred to Pediatrics department, MGM Hospital, Warangal 
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of death16. Extra-pulmonary tubercular manifestations 
occurred in 46 to 79 per cent of patients in another 
study4. In the present group, only one patient exhibited 
granulomatous disease of brain which presented as 
tuberculosis in the brain. One patient among LTPs 
developed pneumonia. Bacterial pneumonitis has 
been reported as an opportunistic infection in 1.8 per 
cent of a large southern Indian cohort of HIV-positive 
patients1.
 An increase in the incidence (5 to 10%) of non-
Hodgkin lymphoma (NHLs) in HIV-infected population 
is reported17. In the present study, one LTP developed 
Burkitt’s lymphoma and died within 6 months. Burkitt’s 
lymphoma is a high-grade aggressive subgroup of non-
Hodgkin’s lymphoma and is manifested as small, non-
cleaved, diffuse, undifferentiated malignant cells of 
lymphoid origin18. Its association with Epstein-Barr 
virus (EBV) varies from 25 to 80 per cent 16. As per the 
CDC AIDS case definition for surveillance, patients 
with CD4 mean count < 200 cell/µl may develop 
Burkitt’s lymphoma. But in the present study, the 
lone patient who developed Burkitt’s lymphoma had 
a high CD4 count amounting to >700 cell/µl. Another 
death occurred due to toxoplasmosis of brain at CD4 
count above >700 cell/µl. CNS toxoplasmosis has 
been the most common OI in HIV patients1. Although 
with differing frequencies chronic diarrhoea, pyrexia 
of unknown origin, chronic parotitis, pruritic popular 
eruption (PPE), have been reported in Indian HIV 
paediatric patients with differing frequencies2.
 Haematologic abnormalities are among the most 
common manifestations of HIV/AIDS infection in 
children. A variety of such abnormalities associated 
with HIV infection was reported in different studies19,20. 
In the present study, both the groups showed 
hematological abnormalities, HIV infected children 
showed 68 per cent RBC abnormal morphology14 and 
the microcytosis with hypochromasia being the most 
frequently reported abnormality21. Clinically significant 
haematological abnormalities are common in HIV 
patients and are mainly due to impaired haematopoiesis, 
immune mediated cytopenia and altered coagulation 
mechanisms. Decline of CD4 counts below 200 cells/
µl increases the risk of anaemia21.
 In the present small group of perinatally HIV 
infected children, approximately one-fourth survived 
beyond 14 yr of age in the absence of ART therapy, 
and three-fourth survived beyond 9 yr of age with ART 
therapy. The present findings suggest that persistent 
low level viral replication is not necessarily associated 
with disease progression if it is efficiently controlled 
over time. Long term survivors of HIV provide a ray 
of hope indicating that it is possible to live with HIV 
without progressing to AIDS. Further longitudinal 
studies with a large cohort need to be done to confirm 
these findings.
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